

## Systematic Review

## THE USE OF DEXMEDETOMIDINE, MIDAZOLAM, AND KETAMINE IN THE PREVENTION OF EMERGENCE AGITATION IN PEDIATRIC PATIENTS UNDERGOING SURGERY UNDER GENERAL ANESTHESIA

Hanifah Syilfana<sup>1</sup>, Beni Indra<sup>2a</sup>, Rahmani Welan<sup>3</sup>, Rinal Effendi<sup>2</sup>, Erlina Rustam<sup>4</sup><sup>1</sup> Faculty of Medicine, Universitas Andalas, Padang, Indonesia<sup>2</sup> Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia<sup>3</sup> Department of Nutrition Sciences, Faculty of Medicine, Universitas Andalas, Padang, Indonesia<sup>4</sup> Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Andalas, Padang, Indonesia<sup>a</sup> Corresponding author: [beniindra@med.unand.ac.id](mailto:beniindra@med.unand.ac.id)

## ABSTRACT

**Introduction:** Emergence agitation (EA) is a problem that often occurs in pediatric patients during recovery from anesthesia. The cause of EA remained unclear, but the combination of etiologies increases the risk of postoperative agitation. The researchers use various drugs such as ketamine, midazolam, and dexmedetomidine to prevent and treat EA. **Objective:** This review aims to determine the effectiveness of dexmedetomidine, midazolam, and ketamine in preventing emergence agitation in pediatric patients undergoing surgery under general anesthesia. **Methods:** This is a systematic review that looks at the outcomes of randomized controlled trials (RCT) studies that tested how well dexmedetomidine, midazolam, and ketamine worked at keeping pediatric patients from becoming agitated during emergence. Literature was collected through Google Scholar and PubMed using the keywords Pediatric, Children, Dexmedetomidine, Ketamine, Midazolam, Emergence Agitation, Emergence Delirium, Postoperative Agitation, and Postoperative Delirium and published within the last ten years (2011–2021) in English or Indonesian. The researchers excluded articles that were not available in full, as well as literature reviews. **Results:** Based on the specified database and keywords identified, there were 695 articles. This literature study included thirteen articles that met the inclusion criteria. Ten articles examined the effectiveness of dexmedetomidine, four reviewed the effectiveness of midazolam, and three examined the effectiveness of ketamine. **Conclusion:** According to the ten reviewed articles, administering dexmedetomidine or ketamine reduced the incidence of emergence agitation in children. However, the administration of midazolam yielded inconsistent results. To evaluate the optimal dosage, route, and timing of dexmedetomidine, midazolam, and ketamine in preventing EA, further studies are necessary.

**Keywords:** Dexmedetomidine; Emergence Agitation; Ketamine; Medicine; Midazolam; Pediatric

## ABSTRAK

**Latar belakang:** *Emergence agitation* (EA) menjadi salah satu masalah yang sering terjadi pada pasien anak-anak saat pemulihan dari anestesi. Penyebab terjadinya EA belum dapat diketahui dengan pasti, namun kombinasi dari etiologi diduga meningkatkan risiko untuk terjadi agitasi pasca operasi. Berbagai obat digunakan untuk pencegahan maupun pengobatan EA di antaranya ketamine, midazolam, dan dexmedetomidine. **Tujuan:** Tinjauan ini bertujuan untuk mengetahui efektivitas Dexmedetomidine, Midazolam, dan Ketamin pada pencegahan *Emergence Agitation* pada pasien anak yang menjalani pembedahan dengan anestesi umum. **Metode:** Studi ini merupakan tinjauan sistematis yang menelaah hasil penelitian *randomized controlled trial* RCT mengenai efektivitas dexmedetomidine, midazolam, dan ketamin terhadap pencegahan *Emergence Agitation* pada pasien anak. Pencarian literatur dilakukan melalui basis data Google Scholar dan PubMed dengan kata kunci *Pediatric, Children, Dexmedetomidine, Ketamine, Midazolam, Emergence Agitation, Emergence Delirium, Postoperative Agitation, dan Postoperative Delirium* yang diterbitkan dalam kurun waktu 10 tahun terakhir (2011 – 2021), menggunakan Bahasa Inggris atau Bahasa Indonesia. Artikel yang tidak bisa didapatkan secara lengkap dan merupakan studi literature review akan dieksklusi. **Hasil:** Berdasarkan database dan keyword yang telah ditetapkan, teridentifikasi 695 artikel. Tiga belas artikel yang memenuhi kriteria inklusi dan dimasukkan dalam studi

literatur ini. Sepuluh artikel meneliti efektivitas dexmedetomidine, empat artikel menilai efektivitas midazolam, serta tiga artikel meneliti tentang efektivitas ketamin. **Kesimpulan:** Berdasarkan sepuluh jurnal yang telah ditelaah, pemberian dexmedetomidine maupun ketamin dapat menurunkan angka kejadian emergence agitation pada anak, namun hasil yang tidak konsisten dilaporkan pada pemberian midazolam. Studi lebih lanjut diperlukan untuk mengevaluasi dosis, rute, dan waktu pemberian yang optimal dari pemberian dexmedetomidine, midazolam, dan ketamin dalam pencegahan EA.

**Kata kunci:** *Dexmedetomidine; Emergence Agitation; Ketamin; Midazolam; Obat; Pasien Anak*

**Article info:** Received: June 21, 2023; Revised: January 24, 2024; Accepted: April 1, 2024; Published: July 29, 2024

## INTRODUCTION

Recovery from general anesthesia is a time of physiological stress for many patients. Perioperative morbidity and mortality are higher in children than in adults. One of the complications after anesthesia in pediatric patients is Emergence Agitation (EA), which has been described as the most observed complex of psychomotor perceptual disturbances and agitation in the early post-anesthesia period (1). This is a common problem in pediatric patients recovering from anesthesia. The incident began to appear since the discovery of inhalation agents, and it is estimated to occur around 10–80% globally in the children's population, with the highest range occurring at preschool age (2).

Agitation appears within the first 30 minutes of recovery, lasts about 5–15 minutes, and can go away independently. However, if it is not handled correctly, it can cause various problems for the patient or medical personnel, including the release of the catheter or endotracheal tube, re-bleeding at the operating site, increasing recovery time in the recovery room, and increasing parental concern and anxiety regarding the clinical condition of their children (3).

The cause of EA remains unclear, but a combination of etiologies increases the risk of postoperative agitation. Three major categories present risk factors associated with EA: patient-related, anesthesia-related, and surgery-related.

Patient-related risk factors include preschool age and preoperative anxiety (4). Risk factors for EA associated with anesthesia include anesthetic agents and a rapid recovery time. EA risk factors for surgery include ear, nose, throat (ENT), and eye surgical procedures. Patients with high postoperative pain scores frequently report EA events (5). Dysregulation of the dopaminergic, serotonergic, noradrenergic, and GABAergic systems mediates the pathophysiological abnormalities that underlie EA (6).

The majority of nonpharmacological EA prevention focuses on reducing preoperative anxiety. Nonpharmacological intervention is to create an environment with temperature, lighting, a comfortable atmosphere, hypnosis, and music therapy (7). Parents' presence during induction is constantly effective in reducing children's anxiety (8). Ketamine, midazolam, and dexmedetomidine are among the drugs used to prevent and treat EA. Dexmedetomidine is an  $\alpha_2$ -adrenergic receptor agonist with sedation, anxiolytic, analgesic, and amnesiac effects and does not depress the respiratory system. Various prospective studies have shown that dexmedetomidine can significantly reduce the incidence of EA in pediatric patients after the use of inhalation anesthetics (9). Administration of dexmedetomidine may be accompanied by hemodynamic changes, including a decreased heart rate and decreased blood pressure. The


sympatholytic effect of dexmedetomidine may be responsible for this (10).

Midazolam is a widely used benzodiazepine premedication agent, particularly in pediatric anesthesia. People believe that midazolam can lower the incidence of EA by lowering the level of pre-operative anxiety (11). There is ongoing debate about the effectiveness of midazolam in reducing risk (12). Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, provides analgesia and sedation with minimal respiratory depression and prevents central sensitization to painful stimulation. Ketamine also works by inhibiting glutamate release (13). This is what makes the authors interested in conducting a study of the effectiveness of dexmedetomidine, midazolam, and ketamine in preventing emergence agitation in pediatric patients undergoing surgery under general anesthesia (14).

## METHODS

The research protocol for this literature review uses the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) Method. While PRISMA includes flow diagrams for both systematic review and meta-analysis, it's important to note that this study's analysis is exclusively focused on a systematic review approach. The decision to refrain from meta-analysis was due to heterogeneity among included studies in terms of study designs, outcome measures, and population characteristics. Furthermore, the researchers observed limitations in data availability and quality across studies, which made a quantitative synthesis through meta-analysis impractical. Therefore, the researchers performed a narrative synthesis of the findings from the included studies to provide a comprehensive overview and qualitative

synthesis of the evidence. The study began with participants, interventions, comparators, outcomes (PICO), research questions (RQ), and criteria used to develop this script. The PubMed and Google Scholar databases were comprehensively reviewed to identify relevant research published between 2011 and 2021 using the keywords that have been determined.



**Figure 1.** PRISMA flow diagram

Articles were searched with the following keywords: “pediatric,” “children,” “dexmedetomidine,” “ketamine,” “midazolam,” “emergence agitation,” “emergence delirium,” “postoperative agitation,” “postoperative

delirium.” Studies restricted to randomized controlled trials (RCTs), articles published in English or in Bahasa Indonesia, assessing the effectivity of dexmedetomidine, midazolam, or ketamine compared with placebo or other anesthetic drugs on the incidence of emergence agitation, and involving EA assessment using Pediatric Anesthesia Emergence Delirium (PAED) scales.

Studies without full-text content, observational studies, case series, case reports, correspondence, reviews, and animal studies were excluded. Furthermore, the researchers will screen the obtained articles based on their title and abstract.

Data extraction tools guide the extraction of information from records according to research objectives. The data extracted in each piece if literature includes the primary author, year of publication, sample, number of pieces, surgical procedure, anesthetic drug intervention (time of administration, dose, route of administration), and outcomes of EA.

## RESULTS AND DISCUSSION

Literature or article searches were carried out through the Pubmed and Google Scholar databases using the keywords ‘Pediatric,’ ‘Children,’ ‘Dexmedetomidine,’ ‘Ketamine,’ ‘Midazolam,’ ‘Emergence Agitation,’ ‘Emergence Delirium,’ ‘Postoperative Agitation,’ ‘Postoperative Delirium’ and found out 695 articles. Then the elimination of articles was carried out using the inclusion and exclusion criteria. The inclusion criteria include the date of publication of the article in the last ten years, starting from 2011 to 2021, in English or Indonesian; the article is primary literature in complete text form; articles discussing the effectiveness of dexmedetomidine, midazolam, and ketamine on preventing the emergence of agitation have

been included after reviewing through the titles and abstracts; and there remain 13 articles.

Ten articles discuss the effectiveness of dexmedetomidine in preventing EA. Four articles examined the efficacy of midazolam, and three articles investigated the efficacy of ketamine against EA.

**Table 1.** Main Characteristics of the Included Studies

Author	Participants	Age	Type of Surgery
Abdelaziz, et al (2016)(15)	105	1 – 7 years	Strabismus
Chen et al. (2013)(16)	78	2 – 7 years	Strabismus
Chen et al. (2018)(17)	100	3-7 years	Inguinal hernia
Hauber, et al (2015)(18)	382	4 – 10 years	Tonsillectomy
Lin et al. (2016)(19)	90	1 – 8 years	Cataract
Makkar, et al (2015)(20)	100	2-8 years	Infra-umbilical
Soliman, et al (2015)(21)	150	4-14 years	Adenotonsillectomy
Begum et al. (2019)(22)	48	2 – 12 years	Abdomen
Bilgen, et al (2014)(23)	78	1 – 8 years	Urology
Ozcan, et al (2014)(24)	62	2 – 7 years	Inguinal hernia repair
Yao et al. (2020)(25)	153	2 – 6 years	Strabismus
Hanna, et al (2018)(26)	80	2 – 9 years	Elective surgery with a minimum duration of 2 hours
Yi et al. (2021)(27)	120	3 – 10 years	Adenotonsillectomy

*Dexmedetomidine* can reduce the incidence of EA, based on the ten articles reviewed. Previous studies support this. Research conducted by Hendrawan et al. in 2013 showed that dexmedetomidine at a dose

of 0.2 µg/kgBW could reduce the incidence of delirium while recovering from general anesthesia in pediatric patients. The incidence of agitation was observed in 4.8% of patients receiving an intravenous dexmedetomidine dose of 1 µg/kg, compared to 47.6% in the placebo group (28). One potential explanation is that dexmedetomidine is an α(2)-adrenoceptor agonist with several analgesic,

anxiolytic, and sedative properties. Binding to postsynaptic 2 adrenergic receptors at the locus ceruleus mediates its soothing and analgetic effects (29). The mechanism by which dexmedetomidine prevents the occurrence of EA is because dexmedetomidine decreases the secretion of noradrenaline from the locus ceruleus and facilitates the release of inhibitory neurotransmitters, namely GABA.

**Table 2.** Outcomes of Emergence Agitation

Author	Group	Dosage	Route	Time Administration	Outcomes
Abdelaziz, et al (2016)	DEX	1 mcg/kg	Intranasal	After induction	The incidence of EA DEX (12%)* Midazolam (21%)* Placebo (47%)
	Midazolam	0,1 mg/kg	Intranasal	After induction	
	Placebo	NS	Infusion		
Chen et al. (2013)	DEX	1 mcg/kg	Intravenous	After induction	The incidence of EA DEX (11%)* Ketamine (22%)* Placebo (46%)
	Ketamine	1 mg/kg	Intravenous	After induction	
	Placebo	NS	Infusion		
Chen et al. (2018)	DEX (D1)	0.25 mcg/kg	Bolus injection	After induction	The incidence of EA D1 (5%) D2 (5%) D3 (0%)* D4 (0%)* Placebo (30%)
	DEX (D2)	0.5 mcg/kg	Bolus injection	After induction	
	DEX (D3)	0.75 mcg/kg	Bolus injection	After induction	
	DEX (D4)	1 mcg/kg	Bolus injection	After induction	
	Placebo	NS	Infusion		
Hauber, et al (2015)	DEX	0.5 mcg/kg	Bolus injection	5 min. Before the end of the surgery	The incidence of EA DEX (36%)* Placebo (66%)
	Placebo	NS	Infusion		
Lin et al. (2016)	DEX (D1)	1 mcg/kg	Intranasal	45 min. before induction	The incidence of EA D1 (23,3%)* D2 (10%)* Placebo (80%)
	DEX (D2)	2 mcg/kg	Intranasal	45 min. before induction	
	Placebo	NS	Infusion		
Makkar, et al (2015)	DEX	0.3 mcg/kg	Intravenous	15 min. before the end of surgery	The incidence of EA DEX (9.4%)* Propofol (13.9%) Placebo (40.6%)
	Propofol	1 mg/kg	Bolus Injection	5 min. Before the end of the surgery	
	Placebo	NS			
Soliman, et al (2015)	DEX	0.5 mcg/kg + 0,1-0,3 mcg/kg/h	Intravenous for 10 min.	after induction	The incidence of EA DEX (8%)* Placebo (38,66%)
	Placebo	NS	Infusion		
Begum et al. (2019)	DEX (D1)	0.4 mcg/kg	Bolus for 10 min.	after intubation	The incidence of EA D1 (20%) D2 (50%)
	DEX (D2)	0.4 mcg/kg/h	Intravenous	during surgery	
Bilgen et al. (2014)	Ketamine	2 mg/kg	Intranasal	before induction	The incidence of EA Ketamine (3,8%)* Alfentanil (36%) Placebo (40%)
	Alfentanil	10 mcg/kg	Intranasal	before induction	
	Placebo	NS	Infusion		
Ozcan, et al (2014)	Ketamine	0.25 mg/kg	Intravenous	10 min. before the end of surgery	PAED scores were similar between the ketamine, midazolam, and control groups
	Midazolam	0.03 mg/kg	Intravenous	10 min. Before the end of the surgery	
	Placebo	NS	Infusion		

**Continuation of Table 2. Outcomes of Emergence Agitation**

Author	Group	Dosage	Route	Time Administration	Outcomes
Yao, et al (2020)	DEX	2 mcg/kg	Intranasal	45 min. before induction	The incidence of EA DEX (11,5%)*
	Midazolam	0.5 mg/kg	Oral	30 min. before induction	Midazolam (44%) Placebo (49%)
	Placebo	NS	Infusion		
Hanna, et al (2018)	Midazolam	0.5 mg/kg	Oral	Premedication	The incidence of EA Midazolam (31.58%)
	Zolpidem	0.25 mg/kg	Oral	Premedication	Zolpidem (23.81%)
Yi et al. (2021)	DEX (D1)	0.5 mcg/kg	Intravenous	after intubation	There was no significant difference in the incidence of EA between groups D1 and D2.
	DEX (D2)	1 mcg/kg	Intravenous	after intubation	

**A Abbreviation: DEX: dexmedetomidine; NS: normal saline**

\* $p < 0,005$

Dexmedetomidine may cause bradycardia or hypotension in some patients, especially when given rapidly by the intravenous route, but intranasal dexmedetomidine has a slower and more gradual onset than intravenous administration (30).

Adults and children commonly use midazolam as a premedication agent to provide anxiolysis, sedation, and amnesia. However, this study's effect on EA was inconsistent. This is in line with previous research. In a study conducted by Cho et al. in 2014, it was reported that intravenous administration of 0.03 mg/kg and 0.05 mg/kg midazolam before the end of surgery can reduce the incidence compared to placebo (31).

In addition, the results of research conducted by Kawai et al. in 2019 stated that giving Midazolam 0,1 mg/kg 30 minutes before the end of the surgical procedure significantly reduces the incidence (12). In contrast, preoperative administration of oral midazolam at a dose of 0.5–1 mg/kg does not reduce the risk of EA because the duration of effective sedation does not last until the postoperative period (11). One explanation is that the fast action of midazolam premedication wears off before the end of the lengthy procedure (13).

Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that provides analgesia and sedation with minimal

respiratory depression and prevents central sensitization to painful stimulation (13). Providing analgesia and sedation during recovery may be essential factors in reducing the incidence of EA after sevoflurane anesthesia. Ketamine has sedative and amnestic properties, and it exhibits vigorous analgesic activity at subanaesthetic doses (32). This study's results demonstrate that ketamine can lower the incidence of EA, with the exception of surgery, where a caudal block reduces pain (24). Demir et al.'s 2018 research revealed that patients undergoing rhinoplasty surgery who received intravenous 0.5 mg/kg ketamine had a lower EA incidence rate of 8.6% compared to the placebo group's 54.3% (33).

The results of this study have limitations due to factors inherent in the research methodology and the number of articles that specifically address this topic.

## SUMMARY

Dexmedetomidine reduces the incidence of post-anesthesia agitation. Intranasal administration is an effective and noninvasive route for administering dexmedetomidine to pediatric patients. Studies of midazolam's effectiveness on the incidence of EA have reported inconsistent findings. One explanation is that the fast action of midazolam premedication wears off before the end of the

lengthy procedure. Further studies are needed to evaluate the optimal dosage, route, and timing of administration of midazolam for preventing EA. Ketamine significantly reduced the incidence of EA, but adding ketamine to the caudal block under sevoflurane anesthesia showed no further effect on EA.

### Acknowledgement

We would like to thank the Faculty of Medicine, Universitas Andalas, and Dr. M. Djamil General Hospital for their support in conducting this research.

### Conflict of Interest

There is no conflict of interest.

### Funding

This research did not receive any funding.

### Authors' Contributors

All authors have contributed to all processes in this research.

### REFERENCES

1. Moore AD, Anghelescu DL. Emergence Delirium in Pediatric Anesthesia. Vol. 19, Pediatric Drugs. 2017. p. 11–20. [[PubMed](#)]
2. Mohkamkar M, Farhodi F, Alam-Sahebpour A, Mousavi SA, Khani S, Shahmohammadi S. Postanesthetic Emergence Agitation in Pediatric Patients under General Anesthesia. *Iran J Pediatr* [Internet]. 2014; 24(2): 184–90. [[PubMed](#)]
3. Mehrotra S. Postoperative anaesthetic concerns in children: Postoperative pain, emergence delirium and postoperative nausea and vomiting. Vol. 63, *Indian Journal of Anaesthesia*. Wolters Kluwer. 2019. p. 763–70. [[PubMed](#)] [[WebPage](#)]
4. Lee SJ, Sung TY. Emergence agitation: Current knowledge and unresolved questions. *Korean J Anesthesiol*. 2020 Dec 1;7 3(6): 471–85. [[PubMed](#)] [[WebPage](#)]
5. Menser C, Smith H. Emergence agitation and delirium: Considerations for epidemiology and routine monitoring in pediatric patients. Vol. 13, *Local and Regional Anesthesia*. 2020. p. 73–83. [[PubMed](#)]
6. De Almeida RMM, Ferrari PF, Parmigiani S, Miczek KA. Escalated aggressive behavior: Dopamine, serotonin and GABA. In: *European Journal of Pharmacology*. 2005. p. 51–64. [[PubMed](#)] [[Science Direct](#)]
7. Kusnugroho D, Pardede B. Pencegahan Emergence Agitation Pasca-operasi pada Pasien Anak. *CDK-282*. 2020;47(1):16–23. [[WebPage](#)]
8. Heilbrunn BR, Wittern RE, Lee JB, Pham PK, Hamilton AH, Nager AL. Reducing anxiety in the pediatric emergency department: A comparative trial. In: *Journal of Emergency Medicine*. 2014. p. 623–31. [[PubMed](#)] [[WebPage](#)]
9. Shi M, Miao S, Gu T, Wang D, Zhang H, Liu J. Dexmedetomidine for the prevention of emergence delirium and postoperative behavioral changes in pediatric patients with sevoflurane anesthesia: A double-blind, randomized trial. *Drug Des Devel Ther*. 2019; 13: 897–905. [[PubMed](#)] [[WebPage](#)]
10. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Vol. 56, *Clinical Pharmacokinetics*. Springer International Publishing; 2017. p. 893–913. [[PubMed](#)]

11. Dahmani S, Delivet H, Hilly J. Emergence delirium in children: An update. Vol. 27, *Current Opinion in Anaesthesiology*. 2014. p. 309–15. [[PubMed](#)] [[WebPage](#)]
12. Kawai M, Kurata S, Sanuki T, Mishima G, Kiriishi K, Watanabe T, et al. The effect of midazolam administration for the prevention of emergence agitation in pediatric patients with extreme fear and non-cooperation undergoing dental treatment under sevoflurane anesthesia, a double-blind, randomized study. *Drug Des Devel Ther*. 2019; 13: 1729–37. [[PubMed](#)] [[WebPage](#)]
13. Kanaya A. Emergence agitation in children: risk factors, prevention, and treatment. Vol. 30, *Journal of Anesthesia*. 2016. 30(2). p. 261–7. [[PubMed](#)]
14. Mason KP. Paediatric emergence delirium: A comprehensive review and interpretation of the literature. Vol. 118, *British Journal of Anaesthesia*. 2017. 118(3). p. 335–43. [[PubMed](#)] [[WebPage](#)]
15. Abdelaziz HMM, Bakr RH, Kasem AA. Effect of intranasal dexmedetomidine or intranasal midazolam on prevention of emergence agitation in pediatric strabismus surgery: A randomized controlled study. *Egypt J Anaesth*. 2016 Jul 1; 32(3): 285–91. [[WebPage](#)]
16. Chen JY, Jia JE, Liu TJ, Qin MJ, Li WX. Comparison of the effects of dexmedetomidine, ketamine, and placebo on emergence agitation after strabismus surgery in children. *Canadian Journal of Anesthesia*. 2013 Apr; 60(4): 385–92. [[PubMed](#)] [[WebPage](#)]
17. Chen F, Wang C, Lu Y, Huang M, Fu Z. Efficacy of different doses of dexmedetomidine as a rapid bolus for ketamine versus alfentanil following midazolam in preventing emergence children: A double-blind, prospective, randomized study. *BMC Anesthesiol*. 2018 Aug 7; 18(1). [[PubMed](#)]
18. Hauber JA, Davis PJ, Bendel LP, Martyn S V., McCarthy DL, Evans MC, et al. Dexmedetomidine as a rapid bolus for treatment and prophylactic prevention of emergence agitation in anesthetized children. *Anesth Analg*. 2015 Nov 1; 121(5): 1308–15. [[PubMed](#)] [[WebPage](#)]
19. Lin Y, Chen Y, Huang J, Chen H, Shen W, Guo W, et al. Efficacy of premedication with intranasal dexmedetomidine on inhalational induction and postoperative emergence agitation in pediatric undergoing cataract surgery with sevoflurane. *J Clin Anesth*. 2016 Sep 1; 33: 289–95. [[PubMed](#)]
20. Makkar JK, Bhatia N, Bala I, Dwivedi D, Singh PM. A comparison of single dose dexmedetomidine with propofol for the prevention of emergence delirium after desflurane anaesthesia in children. *Anaesthesia*. 2016 Jan 1; 71(1): 50–7. [[PubMed](#)] [[WebPage](#)]
21. Soliman R, Alshehri A. Effect of dexmedetomidine on emergence agitation in children undergoing adenotonsillectomy under sevoflurane anesthesia: A randomized controlled study. *Egypt J Anaesth*. 2015 Oct 1; 31(4): 283–9. [[Science Direct](#)]
22. Begum U, Singh P, Naithani B, Singh V, Singh G, Tiwari T. Dexmedetomidine as bolus or low-dose infusion for the prevention of emergence agitation with sevoflurane anesthesia in pediatric patients. *Anesth Essays Res*. 2019; 13(1): 57. [[PubMed](#)] [[WebPage](#)]
23. Bilgen S, Köner Ö, Karacay S, Sancar NK, Kaspar EC, Sözübir S. Effect of agitation in children after sevoflurane anaesthesia: A prospective randomized



- clinical trial. *Journal of International Medical Research*. 2014 Dec 20; 42(6): 1262–71. [[PubMed](#)] [[WebPage](#)]
24. Ozcan A, Kaya AG, Ozcan N, Karaaslan GM, Er E, Baltaci B, et al. Effects of ketamine and midazolam on emergence agitation after sevoflurane anaesthesia in children receiving caudal block: a randomized trial. *Brazilian Journal of Anesthesiology (English Edition)*. 2014 Nov; 64(6): 377–81. [[PubMed](#)]
25. Yao Y, Sun Y, Lin J, Chen W, Lin Y, Zheng X. Intranasal dexmedetomidine versus oral midazolam premedication to prevent emergence delirium in children undergoing strabismus surgery: A randomised controlled trial. *Eur J Anaesthesiol*. 2020 Dec 1; 37(12): 1143–9. [[PubMed](#)] [[WebPage](#)]
26. Hanna AH, Ramsingh D, Sullivan-Lewis W, Cano S, Leiter P, Wallace D, et al. A comparison of midazolam and zolpidem as oral premedication in children, a prospective randomized double-blinded clinical trial. *Paediatr Anaesth*. 2018 Dec 1; 28(12): 1109–15. [[PubMed](#)]
27. Yi W, Li J, Zhuang Y, Wan L, Li W, Jia J. The effect of two different doses of dexmedetomidine to prevent emergence agitation in children undergoing adenotonsillectomy: a randomized controlled trial. *Brazilian Journal of Anesthesiology (English Edition)*. 2022 Jan 1; 72(1): 63–8. [[PubMed](#)]
28. Hendrawan C, Arif SK. Efek Dexmedetomidine 0,2 ug/kgbb Intravena terhadap Insiden Delirium saat Pulih Sadar dari Anestesi Umum pada Pasien Pediatrik. *Jurnal Anestesiologi Indonesia*. 2013; V(2). [[WebPage](#)]
29. Wang W, Huang P, Gao W, Cao F, Yi M, Chen L, et al. Efficacy and Acceptability of Different Auxiliary Drugs in Pediatric Sevoflurane Anesthesia: A Network Meta-analysis of Mixed Treatment Comparisons. *Sci Rep*. 2016 Nov 10; 6. [[PubMed](#)] [[WebPage](#)]
30. Peng W, Zhang TJ. Dexmedetomidine decreases the emergence agitation in infant patients undergoing cleft palate repair surgery after general anesthesia. *BMC Anesthesiol*. 2015 Oct 13; 15(1). [[PubMed](#)] [[WebPage](#)]
31. Eun Jung C, Seung Zhoo Y, Jang Eun C, Hye Won L. cho2014. *Anesthesiology*. 2014; V(6): 1354–1351.
32. Jiang M, Wang MH, Wang X Bin, Liu L, Wu JL, Yang XL, et al. Effect of intraoperative application of ketamine on postoperative depressed mood in patients undergoing elective orthopedic surgery. *J Anesth*. 2016 Apr 1; 30(2): 232–7. [[PubMed](#)] [[WebPage](#)]
33. Demir CY, Yuzkat N. Prevention of Emergence Agitation with Ketamine in Rhinoplasty. *Aesthetic Plast Surg*. 2018 Jun 1; 42(3): 847–53. [[PubMed](#)]